Board of directors
Peter Mørch Eriksen
Chairman of the board
Peter has over 20 years of international experience in the medtech and life science sectors. He has previously been CEO of BioPorto A/S and held senior roles at Medtronic in both the U.S. and Denmark, including Vice President. Peter has a strong track record in driving growth, leading restructurings, and securing funding in complex, technology-driven organizations. With a background in accounting and executive management training, he combines financial expertise with strategic leadership. He also serves as Chairman of Monsenso A/S and AptaShape ApS, Director of PME Holding ApS, and is a member of the Medical Device and Diagnostics Advisory Committee at Cincinnati Children’s Hospital Medical Center.
Born in 1960. Chairman of the board since 2021.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 115,669 and 87,500 warrants (Partly owned via PME Holding ApS).
Mats Thorèn
Vice chairman of the board
Mats brings 25 years of financial market experience, specializing in healthcare through roles in equity analysis and corporate finance. He has spent 20 years as a Healthcare investment expert, working with firms like Nalka Life Science AB and MedCap AB, and now leads Vixco Capital. Mats holds board positions at Xbrane BioPharma AB, Arcoma AB, Herantis Pharma Oy, BioPorto A/S and C-Rad AB with past board roles at Duocort AB, Cellartis AB, and others. His educational background includes Economics, focusing on Accounting and Financial Economics, and medical studies at the Karolinska Institute in Stockholm.
Born in 1971. Board member since 2021.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 741 and 0 warrants.
Andreas Kjaer
Member of the board
Andreas is an MD, PhD, DMSc, and professor at the University of Copenhagen as well as chief physician at Rigshospitalet, the National University Hospital of Denmark. His research is focused on molecular imaging with PET and PET/MRI in cancer and cardiovascular disease and his achievements include development of several new tracers that have reached first-in-humans clinical use. He is the holder of an ERC Advanced Grant, has published 700 peer-review articles, and has received multiple prestigious scientific awards throughout the years. Andreas also holds an MBA from Copenhagen Business School.
Born in 1963. Board member since 2018.
Dependent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 2,126,107 (owned via Life Science Aps) and privately 121,400 warrants.
Michael Engsig
Member of the board
Michael has extensive experience within the pharmaceutical industry with 20+ years of experience in both foreign capital markets and publicly listed companies. This includes a successful track record in general management, R&D, and commercial functions. Since 2019 Michael has been CEO at Nykode Therapeutics, Norway. Michael holds a M.Sc. in chemistry with a specialization in biotechnology from the Technical University of Denmark (DTU) and a graduate diploma in Business Administration (HD) from Copenhagen Business School (CBS).
Born in 1972. Board member since 2023.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 0 and 7,500 warrants.
Donna Haire
Member of the board
Donna Haire is an accomplished board director and Chief Executive Officer of The Eriah Group, Inc., a global consulting firm specializing in turn-key R&D operations, including regulatory, quality, clinical, and medical affairs for drugs, biologics, medical devices, in vitro diagnostics, and combination products. With over 30 years of leadership experience in healthcare, pharmaceuticals, and medical devices, she has a proven track record of designing, developing, and successfully commercializing innovative products. Donna currently serves on the boards of Sedana Medical AB and BioPorto A/S. Her previous executive roles include Executive Vice President of Regulatory and Quality at On Target Laboratories, Vice President, Head of Medical Care Global Regulatory Affairs at Bayer, and Senior Vice President of Regulatory, Quality, Clinical, and Medical Affairs at AngioDynamics. She held senior leadership roles at Philips Healthcare, Medtronic, and STERIS, and was appointed as a U.S. regulatory expert to lead international trade negotiations. She served on AdvaMed’s Technical and Regulatory Board Committee and was an Adjunct Professor at the University of Akron School of Law. Donna holds an M.S. in Biology from Cleveland State University and a B.S. in Biology from The University of Akron.
Donna holds an M.S. in Biology from Cleveland State University and a B.S. in Biology from The University of Akron.
Born in 1969. Board member since 2024.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 0 and 7,500 warrants.
Peter Mørch Eriksen
Chairman of the board
Peter has over 20 years of international experience in the medtech and life science sectors. He has previously been CEO of BioPorto A/S and held senior roles at Medtronic in both the U.S. and Denmark, including Vice President. Peter has a strong track record in driving growth, leading restructurings, and securing funding in complex, technology-driven organizations. With a background in accounting and executive management training, he combines financial expertise with strategic leadership. He also serves as Chairman of Monsenso A/S and AptaShape ApS, Director of PME Holding ApS, and is a member of the Medical Device and Diagnostics Advisory Committee at Cincinnati Children’s Hospital Medical Center.
Born in 1960. Chairman of the board since 2021.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 115,669 and 87,500 warrants (Partly owned via PME Holding ApS).
Mats Thorèn
Vice chairman of the board
Mats brings 25 years of financial market experience, specializing in healthcare through roles in equity analysis and corporate finance. He has spent 20 years as a Healthcare investment expert, working with firms like Nalka Life Science AB and MedCap AB, and now leads Vixco Capital. Mats holds board positions at Xbrane BioPharma AB, Arcoma AB, Herantis Pharma Oy, BioPorto A/S and C-Rad AB with past board roles at Duocort AB, Cellartis AB, and others. His educational background includes Economics, focusing on Accounting and Financial Economics, and medical studies at the Karolinska Institute in Stockholm.
Born in 1971. Board member since 2021.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 741 and 0 warrants.
Andreas Kjaer
Member of the board
Andreas is an MD, PhD, DMSc, and professor at the University of Copenhagen as well as chief physician at Rigshospitalet, the National University Hospital of Denmark. His research is focused on molecular imaging with PET and PET/MRI in cancer and cardiovascular disease and his achievements include development of several new tracers that have reached first-in-humans clinical use. He is the holder of an ERC Advanced Grant, has published 700 peer-review articles, and has received multiple prestigious scientific awards throughout the years. Andreas also holds an MBA from Copenhagen Business School.
Born in 1963. Board member since 2018.
Dependent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 2,126,107 (owned via Life Science Aps) and privately 121,400 warrants.
Michael Engsig
Member of the board
Michael has extensive experience within the pharmaceutical industry with 20+ years of experience in both foreign capital markets and publicly listed companies. This includes a successful track record in general management, R&D, and commercial functions. Since 2019 Michael has been CEO at Nykode Therapeutics, Norway. Michael holds a M.Sc. in chemistry with a specialization in biotechnology from the Technical University of Denmark (DTU) and a graduate diploma in Business Administration (HD) from Copenhagen Business School (CBS).
Born in 1972. Board member since 2023.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 0 and 7,500 warrants.
Donna Haire
Member of the board
Donna Haire is an accomplished board director and Chief Executive Officer of The Eriah Group, Inc., a global consulting firm specializing in turn-key R&D operations, including regulatory, quality, clinical, and medical affairs for drugs, biologics, medical devices, in vitro diagnostics, and combination products. With over 30 years of leadership experience in healthcare, pharmaceuticals, and medical devices, she has a proven track record of designing, developing, and successfully commercializing innovative products. Donna currently serves on the boards of Sedana Medical AB and BioPorto A/S. Her previous executive roles include Executive Vice President of Regulatory and Quality at On Target Laboratories, Vice President, Head of Medical Care Global Regulatory Affairs at Bayer, and Senior Vice President of Regulatory, Quality, Clinical, and Medical Affairs at AngioDynamics. She held senior leadership roles at Philips Healthcare, Medtronic, and STERIS, and was appointed as a U.S. regulatory expert to lead international trade negotiations. She served on AdvaMed’s Technical and Regulatory Board Committee and was an Adjunct Professor at the University of Akron School of Law. Donna holds an M.S. in Biology from Cleveland State University and a B.S. in Biology from The University of Akron.
Donna holds an M.S. in Biology from Cleveland State University and a B.S. in Biology from The University of Akron.
Born in 1969. Board member since 2024.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 0 and 7,500 warrants.